Emergence of Drug Resistance Is Associated With an Increased Risk of Death Among Patients First Starting HAART
September 22, 2006
Robert Hogg of the British Columbia Centre for Excellence in HIV/AIDS and colleagues analyzed the health records of 1,138 HIV-positive people who began highly active antiretroviral therapy from Aug. 1, 1996, through Sept. 30, 1999, to determine the impact of the emergence of drug-resistant mutations on survival rates. The study, which was published in PLoS Medicine, finds that during the follow-up period -- which was an average of five years -- an 18.2% mortality rate, or 207 deaths, occurred. In addition, 26.5% of participants during follow up were identified as being resistant to HAART, the study finds. According to the study, resistance to HAART was associated with a 1.75 times higher mortality rate overall, and when each class of antiretroviral was considered separately, resistance to non-nucleoside reverse transcriptase inhibitors were associated with a 3.02 times higher mortality rate. The researchers concluded that the "emergence of resistance to non-nucleoside reverse transcriptase inhibitors was associated with a greater risk of subsequent death than was emergence of protease inhibitor resistance. Future research is needed to identify the particular subpopulations of men and women at greatest risk and to elucidate the impact of resistance over a longer follow-up period" (Hogg et al., PLoS Medicine, September 2006).
Causes of Death Among Persons With AIDS in the Era of Highly Active Antiretroviral Therapy: New York City
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.